Replies to post #219754 on Avid Bioservices Inc (CDMO)

[Couch]

Should a patient as many do only tolerate a single dose of Obdiva, those patients should be given Bavi.

Then of course the combination of the two could become the SOC.

So Doce. future depends on the Sunrise results as well.

Seems to me if I understand Bavi's MoA sufficiently both drugs/companies may soon be in need of combining their drug with Bavi to secure being or continuing to be the SOC? And Sanofi seems to already understand this likelihood.

And in the new era of combination drugs in the fight against cancer, Peregrine has to first show positive Sunrise results BEFORE additional combination companies come knocking it would seem.

The first look in if acceptable to the FDA should raise the PPS on this speculation alone.

[north40000]

Does the quote from Nilogen/Moffitt:

President & CEO of Nilogen Oncosystems [=Moffit Startup: http://otmc.moffitt.org/startups.aspx ]. "It is an exciting time for the field of immunotherapy and the data we have been generating support that bavituximab has the potential to activate a tumor specific immune response in patients with PD-L1 negative tumors that generally do not respond as well to PD-1 or PD-L1 inhibitors."


appear on the poster from AACR 2015?

If not, where did you get it, and is the data he is speaking about limited to pre-clinical data?

In other words, can you furnish a link to the source of that quote?